within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC01_Cytarabine;

model Cytarabine
  extends Pharmacolibrary.Drugs.ATC.L.L01BC01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01BC01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cytarabine (also known as Ara-C) is a cytosine nucleoside analog used primarily as an antimetabolite chemotherapy agent for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma. It inhibits DNA synthesis in rapidly dividing cells. Cytarabine is an approved and widely used chemotherapy drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from adults with acute myeloid leukemia treated via intravenous infusion; values reflect population pharmacokinetics.</p><h4>References</h4><ol><li><p>Crook, KI, et al., &amp; Papich, MG (2013). The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes. <i>Journal of veterinary pharmacology and therapeutics</i> 36(4) 408–411. DOI:<a href=\"https://doi.org/10.1111/jvp.12008\">10.1111/jvp.12008</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22943060/\">https://pubmed.ncbi.nlm.nih.gov/22943060</a></p></li><li><p>Cornely, OA, et al., &amp; Hodges, MR (2023). Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. <i>The Journal of antimicrobial chemotherapy</i> 78(11) 2645–2652. DOI:<a href=\"https://doi.org/10.1093/jac/dkad269\">10.1093/jac/dkad269</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37681450/\">https://pubmed.ncbi.nlm.nih.gov/37681450</a></p></li><li><p>Eckstein, OS, et al., &amp; McClain, KL (2023). Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine. <i>Pediatric hematology and oncology</i> 40(5) 497–505. DOI:<a href=\"https://doi.org/10.1080/08880018.2022.2137609\">10.1080/08880018.2022.2137609</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36625721/\">https://pubmed.ncbi.nlm.nih.gov/36625721</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cytarabine;
